凯美拉治疗

最新新闻

• J.P. Morgan Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Maintains Target Price $140
  \u5e02\u573a\u8d44\u8baf · 2026/9/28
• 评级变动
  J.P. Morgan Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Announces Target Price $121
  \u5e02\u573a\u8d44\u8baf · 2026/8/8
• 评级变动
  Deutsche Bank Initiates Kymera Therapeutics(KYMR.US) With Hold Rating, Announces Target Price $120
  \u5e02\u573a\u8d44\u8baf · 2026/7/30
• 评级变动
  Stifel Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Maintains Target Price $132
  \u5e02\u573a\u8d44\u8baf · 2026/8/14
• 评级变动
  BofA Securities Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Raises Target Price to $144
  \u5e02\u573a\u8d44\u8baf · 2026/9/14
• 评级变动
  Analysts' Top Healthcare Picks: Metagenomi, Inc. (MGX), Kymera Therapeutics (KYMR)
  TipRanks · 2026/8/11
• 评级变动
  Guggenheim Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Raises Target Price to $135
  \u5e02\u573a\u8d44\u8baf · 2026/7/28
• Form 144 | Kymera Therapeutics(KYMR.US) Officer Proposes to Sell 3.35 Million in Common Stocks
  \u5e02\u573a\u8d44\u8baf · 2026/10/2
• 评级变动
  A Quick Look at Today's Ratings for Kymera Therapeutics(KYMR.US), With a Forecast Between $116 to $139
  \u5e02\u573a\u8d44\u8baf · 2026/8/7
• Kymera Therapeutics(KYMR.US) Officer Sells US$3.41 Million in Common Stock
  \u5e02\u573a\u8d44\u8baf · 2026/10/2
• 评级变动
  Wells Fargo Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Raises Target Price to $151
  \u5e02\u573a\u8d44\u8baf · 2026/8/27
• 评级变动
  Stifel Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Raises Target Price to $152
  \u5e02\u573a\u8d44\u8baf · 2026/9/22
• Piper Sandler Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Maintains Target Price $140
  \u5e02\u573a\u8d44\u8baf · 2026/9/23
• 评级变动
  BofA Securities Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Cuts Target Price to $123
  \u5e02\u573a\u8d44\u8baf · 2026/8/8
• 评级变动
  J.P. Morgan Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Raises Target Price to $140
  \u5e02\u573a\u8d44\u8baf · 2026/9/4
• 评级变动
  A Quick Look at Today's Ratings for Kymera Therapeutics(KYMR.US), With a Forecast Between $128 to $139
  \u5e02\u573a\u8d44\u8baf · 2026/8/6
• Citi Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Raises Target Price to $150
  \u5e02\u573a\u8d44\u8baf · 2026/10/5
• 评级变动
  Wolfe Research Upgrades Kymera Therapeutics(KYMR.US) to Buy Rating, Announces Target Price $180
  \u5e02\u573a\u8d44\u8baf · 2026/9/10
• 评级变动
  J.P. Morgan Sticks to Its Buy Rating for Kymera Therapeutics (KYMR)
  TipRanks · 2026/9/4
• 评级变动
  Guggenheim Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Raises Target Price to $170
  \u5e02\u573a\u8d44\u8baf · 2026/8/31

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。